Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2100 - Random optimization Interactive System based on Kernel learning (RISK) for venous thromboembolism risk assessment in chemotherapy-treated cancer patients


10 Sep 2017


Poster display session


Supportive Care and Symptom Management


Patrizia Ferroni


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


P. Ferroni1, F.M. Zanzotto2, N. Scarpato3, S. Riondino4, F. Guadagni1, M. Roselli5

Author affiliations

  • 1 Dept. Of Human Sciences And Quality Of Life Promotion, San Raffaele Roma Open University, 00166 - Rome/IT
  • 2 Dept. Of Enterprise Engineering, University of Rome Tor Vergata, Rome/IT
  • 3 Dept. Of Human Sciences And Quality Of Life Promotion, San Raffaele Roma Open University, Rome/IT
  • 4 Biomarker Discovery And Advanced Biotechnologies (biodat) Laboratory, IRCCS San Raffaele, Rome/IT
  • 5 Dept. Of Systems Medicine, Policlinico Tor Vergata, 133 - Roma/IT


Abstract 2100


Using a combined approach of Kernel machine-learning (ML) and random optimization (RO) techniques we recently developed a set of predictors (ML-ROs) for VTE risk assessment. Aim of this study was to validate a model incorporating the two best ML-ROs to devise a web-based graphical interface for VTE risk stratification.


Pre-chemotherapy age, sex, tumor site and stage, hematological attributes, fasting blood lipids, glycemic indexes, liver and kidney function, BMI, ECOG, supportive and anti-cancer drugs of 608 cancer outpatients were entered in the model, with numerical attributes analyzed as continuous values. Variables were clustered into groups according to clinical significance, and RO was used to devise their relative weight in final prediction.


VTE occurred in 7.1% of patients. Overall, 6% were at high-risk for VTE, as per current guidelines (Khorana Score (KS) ≥3), 11% of which had VTE during treatment. 42% and 52% were at intermediate (KS 1/2) or low-risk (KS = 0), with VTE rates of 9% and 5%, respectively. Accordingly, the performance of KS, despite a 94% specificity, was characterized by a 9% sensitivity with an area under the ROC curve (AUROC) of 0.589, translating into non-significant positive (+LR) [1.58 (0.48-4.30)] or negative likelihood ratio (-LR) [0.96 (0.83-1.04)]. Conversely, the VTE risk prediction performance of the combined ML model showed a 0.716 AUROC, which was significantly higher than that observed with KS (difference between areas: 0.127, p = 0.0044). At a criterion >1 (risk estimate achieved by both predictors) this combined approach showed significant +LR [2.30 (1.70-2.82)] and -LR [0.46 (0.28-0.69)] and a 4.9 Hazard Ratio (95%CI: 2.5-9.4) with a 6-month VTE rate of 3.4% in the low-risk, compared with 14.9% in the high-risk category.


These results demonstrate that a ML approach, optimizing the relative weight (by RO) of groups of clinical attributes, is of clinical value for VTE risk prediction, performing better than KS. We are now finalizing the architecture of a web service with a graphical interface helping oncologists in the critical phase of decision making.

Clinical trial identification

Not applicable

Legal entity responsible for the study

RISK Research Group


European Social Fund PON03PE_00146_1/10 BIBIOFAR


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.